<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31740545</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>24</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.</ArticleTitle><Pagination><StartPage>e2294</StartPage><EndPage>e2305</EndPage><MedlinePgn>e2294-e2305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008620</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the safety and efficacy of mesenchymal stem cell (MSC)-neurotrophic factor (NTF) cells (NurOwn&#xae;, autologous bone marrow-derived MSCs, induced to secrete NTFs) delivered by combined intrathecal and intramuscular administration to participants with amyotrophic lateral sclerosis (ALS) in a phase 2 randomized controlled trial.</AbstractText><AbstractText Label="METHODS">The study enrolled 48 participants randomized 3:1 (treatment: placebo). After a 3-month pretransplant period, participants received 1 dose of MSC-NTF cells (n = 36) or placebo (n = 12) and were followed for 6 months. CSF was collected before and 2 weeks after transplantation.</AbstractText><AbstractText Label="RESULTS">The study met its primary safety endpoint. The rate of disease progression (Revised ALS Functional Rating Scale [ALSFRS-R] slope change) in the overall study population was similar in treated and placebo participants. In a prespecified rapid progressor subgroup (n = 21), rate of disease progression was improved at early time points (<i>p</i> &lt; 0.05). To address heterogeneity, a responder analysis showed that a higher proportion of treated participants experienced &#x2265;1.5 points/month ALSFRS-R slope improvement compared to placebo at all time points, and was significant in rapid progressors at 4 and 12 weeks (<i>p</i> = 0.004 and 0.046, respectively). CSF neurotrophic factors increased and CSF inflammatory biomarkers decreased in treated participants (<i>p</i> &lt; 0.05) post-transplantation. CSF monocyte chemoattractant protein-1 levels correlated with ALSFRS-R slope improvement up to 24 weeks (<i>p</i> &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSION">A single-dose transplantation of MSC-NTF cells is safe and demonstrated early promising signs of efficacy. This establishes a clear path forward for a multidose randomized clinical trial of intrathecal autologous MSC-NTF cell transplantation in ALS.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This phase II study provides Class I evidence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windebank</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owegi</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna-Yasek</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Yossef S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abramov</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaspi</LastName><ForeName>Haggai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehra</LastName><ForeName>Munish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aricha</LastName><ForeName>Revital</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gothelf</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>From Massachusetts General Hospital Neurological Clinical Research Institute and Harvard Medical School (J.D.B., M.E.C., K.N.), Boston; Mayo Clinic (A.J.W., N.P.S.), Rochester, MN; University of Massachusetts (M.O., D.M.-Y., R.H.B.), Worcester; Brainstorm Cell Therapeutics (Y.S.L., N.A., H.K., R.A., Y.G.), Petach Tikva, Israel; and Tigermed USA (M.M.), Somerset, NJ. robert.brown@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Dec 10;93(24):1028-1029</RefSource><PMID Version="1">31740544</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31740545</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pii">WNL.0000000000008620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">19172693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf Y, Abramov N, Harel A, Offen D. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin Transl Med 2014;3:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108239</ArticleId><ArticleId IdType="pubmed">25097724</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf Y, Kaspi H, Abramov N, Aricha R. miRNA profiling of NurOwn&#xae;: mesenchymal stem cells secreting neurotrophic factors. Stem Cell Res Ther 2017;8:249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678806</ArticleId><ArticleId IdType="pubmed">29116031</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, et al. . Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol 2016;73:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Almeida S, Lu Y, et al. . Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One 2013;8:e76055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797144</ArticleId><ArticleId IdType="pubmed">24143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Cialic R, et al. . Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol 2015;77:75&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Hur J, Lunn JS, et al. . Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci 2016;71:34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, et al. . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 2010;11:178&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Schoenfeld D, Cudkowicz ME, Atassi N. Vital capacity: high test-retest variability in ALS patients with bulbar weakness. J Neurol Sci 2017:381.</Citation></Reference><Reference><Citation>Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2017;195:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214920</ArticleId><ArticleId IdType="pubmed">27494149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014;15:1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">25329189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2013;8:888&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovich-Nikitin I, Ezra A, Barbiro B, Rabinovich-Toidman P, Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS. J Neuroinflammation 2016;13:123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882847</ArticleId><ArticleId IdType="pubmed">27230771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzi P, Domercq M, Brambilla L, et al. . CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426226</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav 2017;7:e00637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou LL, et al. . Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J 2015;34:2633&#x2013;2651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos J, Enlund E, Funcke JB, et al. . miR-146a-mediated suppression of the inflammatory response in human adipocytes. Sci Rep 2016;6:38339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138634</ArticleId><ArticleId IdType="pubmed">27922090</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Zhang Y, Du XF, et al. . Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity. Cell Res 2017;27:882&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518987</ArticleId><ArticleId IdType="pubmed">28429770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>